🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "huge turning point" in the fight against increasingly resistant strains of the pathogen, according to health experts.

An International Health Concern

Cases of gonorrhoea are increasing globally, with estimates suggesting in excess of 82 million instances annually. Especially elevated rates are seen in Africa and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary advancement in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited treatment choices at this time.”

Medical experts are particularly alarmed about the increase in drug-resistant strains. The global health body has listed it as a "high-priority threat". A tracking program revealed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Receive Approval

One new antibiotic, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in recent days for treating gonorrhoea. This infection can lead to major issues, including infertility. Experts hope that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, gained clearance in close succession. This treatment, which is also used to treat urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a unique collaborative effort for medication research. The charitable organization GARDP worked alongside the pharmaceutical company its industry partner to develop it.

“This approval marks a major breakthrough in the therapy of superbug gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Testing Outcomes and Global Access

According to findings published in a major medical journal, zoliflodacin cured more than 90% of genital gonorrhoea infections. This places it at an similar efficacy with the typical regimen, which uses two antibiotics. The trial enrolled hundreds of participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the rights to license and sell the drug in numerous regions with limited resources.

Medical professionals treating patients have voiced hope. The availability of a single-dose, oral treatment like this is hailed as a "revolutionary step" for managing the epidemic. This is considered vital to alleviate the strain of the infection for individuals and to halt the transmission of highly drug-resistant gonorrhoea around the world.